Drugs / NEU-411
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05755191 | May 2023 → Jun 2024 | — | Neuron23 Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06680830 | Jan 2025 → Dec 2027 expected | Parkinson disease | Neuron23 Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-03-24 | Neuron23 Inc. | Results Neuron23 to Present Phase 1 Healthy Volunteer Data of NEU-411, a Brain-penetrant LRRK2 Inhibitor, at AD/PD™ 2025 neuron23.com ↗
NEU-411 was well-tolerated; no serious adverse events were observed, and all adverse events were mild or moderate. |
All press releases naming this drug 2 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NEU-411 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05755191 ↗ |
| Action | Inhibit | “inhibitor of LRRK2 activity” NCT06680830 ↗ |
| Modality | Small molecule | “small molecule inhibitor of LRRK2 activity” NCT06680830 ↗ |
| Route | Oral | “orally administered NEU-411” NCT05755191 ↗ |
| Target | LRRK2 | “inhibitor of LRRK2 activity” NCT06680830 ↗ |